Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07804901 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Asciminib Frontline Risk Adapted

Name: Asciminib Frontline Risk Adapted — clinical trial record (NCT07804901)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ARTIST

StatusNot Yet Recruiting

PhasePhase 2

SponsorProf. Dr. med. Andreas Hochhaus

Started2027-01-01

View on ClinicalTrials.gov ↗

This is a multi-center, prospective, non-randomized but stratified interventional phase II study of newly diagnosed CML patients in chronic phase. All patients will be treated with asciminib 80 mg QD. Patients with unfavorable risk factors will commence dasatinib 80 mg 5 days/week 4 weeks after start of asciminib. The study will be conducted in Germany.

Trial Details

NCT Number	NCT07804901
Lead Sponsor	Prof. Dr. med. Andreas Hochhaus
Conditions	Chronic Myeloid Leukemia (CML)
Enrollment	200 participants
Start Date	2027-01-01
Primary Completion	2030-12-31 (estimated)
Study Completion	2031-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-04